Author

Blach S

December 11, 2021
Progress towards achieving viral hepatitis B and C elimination in the Asia and Pacific region: Results from modelling and global reporting
Summary In 2016, Asia and Pacific countries endorsed action plans for reaching viral hepatitis elimination targets set in the Global Health Sector Strategy (GHSS) for Viral Hepatitis 2016-2021. We examine the region’s progress by modelling disease burden and constructing the cascade of care. Between 2015 and 2020, chronic HBV prevalence declined from 4.69% to 4.30%, […]

Read More
November 27, 2021
HCV disease burden and population segments in Switzerland
Summary Background Switzerland has made strides towards hepatitis C virus elimination, but as of 2019, elimination was not guaranteed. However, political interest in viral hepatitis has been increasing. We sought to develop a better understanding of Switzerland’s progress towards HCV elimination and the profile of remaining HCV-RNA-positive patients. Methods A previously described Markov model was […]

Read More
May 29, 2021
Hepatitis C elimination in Sweden: Progress, challenges and opportunities for growth in the time of COVID‐19
Summary Background & Aims In 2014, the burden of hepatitis C virus (HCV) in Sweden was evaluated, to establish a baseline and inform public health interventions. Considering the changing landscape of HCV treatment, prevention, and care, and in light of the COVID-19 pandemic, this analysis seeks to evaluate Sweden’s progress towards the World Health Organization […]

Read More
August 7, 2020
Impact of COVID-19 on global HCV elimination efforts
Summary Background & Aims Coronavirus disease 2019 (COVID-19) has placed a significant strain on national healthcare systems at a critical moment in the context of hepatitis elimination. Mathematical models can be used to evaluate the possible impact of programmatic delays on hepatitis disease burden. The objective of this analysis was to evaluate the incremental change […]

Read More
July 12, 2020
Tailored screening and dedicated funding for direct acting antiviral drugs: how to keep Italy on the road to hepatitis C virus elimination?
Summary Background and aims Hepatitis C virus (HCV) elimination for Italy is an ambitious, but achievable goal. In Italy, there is political will, which aims to achieve the World Health Organization (WHO) elimination goals recognizing the need to identify undiagnosed individuals in key high-risk groups and in the general population, however there is concern regarding […]

Read More
April 2, 2020
Optimization of hepatitis C virus screening strategies by birth cohort in Italy
Summary Optimization of hepatitis C virus screening strategies by birth cohort in Italy Background and Aims Cost-effective screening strategies are needed to make hepatitis C virus (HCV) elimination a reality. We determined if birth cohort screening is cost-effective in Italy. Methods A model was developed to quantify screening and healthcare costs associated with HCV. The […]

Read More
January 16, 2020
Global prevalence of hepatitis C virus in children in 2018: a modelling study
Summary Background Hepatitis C virus (HCV) prevalence estimates for adults and high-risk groups have been widely published, but the disease burden in children is poorly understood. Direct-acting antiviral drugs, which are considered to be highly effective curative therapies for HCV, are now approved for paediatric patients as young as 3 years. Reliable prevalence estimates for […]

Read More
August 28, 2018
Global, regional, and country-level estimates of hepatitis C virus infection among people who have recently injected drugs
Summary Background and Aims People who have recently injected drugs are a priority population in efforts to achieve hepatitis C virus (HCV) elimination. This study estimated the prevalence and number of people with recent injecting drug use living with HCV, and the proportion of people with recent injecting drug use among all people living with […]

Read More
August 16, 2018
HCV elimination among people who inject drugs. Modelling pre- and post-WHO elimination era
Summary Background Elimination of hepatitis C virus (HCV) among people who inject drugs (PWID) is a costly investment, so strategies should not only focus on eliminating the disease, but also on preventing disease resurgence. The aims of this study are to compute the minimum necessary antiviral therapies to achieve elimination with and without the additional […]

Read More
August 10, 2018
Forecasting Hepatitis C liver disease burden on real life data. Does the hidden iceberg matter to reach the elimination goals?
Summary Background & Aims Advances in direct acting anti-viral treatment of HCV have reinvigorated public health initiatives aimed at identifying affected individuals. We evaluated the possible impact of only diagnosed and linked-to-care individuals on overall HCV burden estimates and identified a possible strategy to achieve the WHO targets by 2030. Methods Using a modelling approach […]

Read More

Author

Blach S

Progress towards achieving viral hepatitis B and C elimination in the Asia and Pacific region: Results from modelling and global reporting

HCV disease burden and population segments in Switzerland

Hepatitis C elimination in Sweden: Progress, challenges and opportunities for growth in the time of COVID‐19

Impact of COVID-19 on global HCV elimination efforts

Tailored screening and dedicated funding for direct acting antiviral drugs: how to keep Italy on the road to hepatitis C virus elimination?

Optimization of hepatitis C virus screening strategies by birth cohort in Italy

Global prevalence of hepatitis C virus in children in 2018: a modelling study

Global, regional, and country-level estimates of hepatitis C virus infection among people who have recently injected drugs

HCV elimination among people who inject drugs. Modelling pre- and post-WHO elimination era

Forecasting Hepatitis C liver disease burden on real life data. Does the hidden iceberg matter to reach the elimination goals?

Useful Links, CDAF

Useful Links, Polaris

Latest News